Shots:

• The EC granted ODD for VO659 for the treatment of spinocerebellar ataxia (SCA). The ODD was based on a EMA’s COMP positive opinion
• The company previously received ODD in Huntington Disease The company focused on the development of RNA modulating therapies for rare neurological disorders
• VO659 is an antisense oligonucleotide product- designed to suppress mutant proteins and slow or halt disease progression

 ­ Ref: PRNewswire | Image: Polaris Partners